Information Provided By:
Fly News Breaks for November 14, 2019
SEEL
Nov 14, 2019 | 08:09 EDT
Benchmark analyst Bruce Jackson initiated coverage of Seelos Therapeutics with a Speculative Buy rating and $4 price target. The early-stage company's lead product candidate, SLS-002 for the treatment of suicidality in Major Depressive Disorder and Post Traumatic Stress Disorder, is looking to enter a potential market of more than $1B, noted Jackson. The completion of a Phase 1 study of SLS-002 is expected in the first quarter of 2020, to be followed by the start of a Phase 2 proof of concept trial in the second quarter, he added.
News For SEEL From the Last 2 Days
There are no results for your query SEEL